Introduction
============

Invasive meningococcal disease (IMD) is a debilitating disease which, despite treatment, has fatality rates of 5%--10% and can induce serious, long-term, physical and neurological sequelae in up to 20% of survivors \[[@B1][@B2][@B3]\]. Therefore, IMD remains a major public concern, although disease incidence is relatively low \[[@B3][@B4]\]. Six of the 12 known serogroups of *Neisseria meningitidis* (MenA, MenB, MenC, MenW, MenX, and MenY) account for practically all IMD cases, but their prevalence varies considerably in time, by region and socio-economic status \[[@B5][@B6]\].

In South Korea, where a national surveillance system is in place, the reported annual number of cases of meningococcal meningitis varied, with six cases documented in 2015 and in 2016, 17 in 2017 and 14 in 2018 \[[@B7]\]. The prevalence of meningococcal serogroups responsible for IMD also changed over time \[[@B8][@B9]\]. MenB was the most prominent serogroup between 2010 and 2016, accounting for 37% of IMD cases, while MenW was responsible for small outbreaks in military personnel, prior to the initiation of a meningococcal vaccination program in 2012 \[[@B9]\].

Vaccination remains the most effective and safe approach to prevent IMD \[[@B4]\]. In South Korea, two quadrivalent meningococcal vaccines are licensed. The MenACWY-CRM (GSK Vaccines Srl, Bellaria-Rosia, Italy) vaccine, conjugated with a non-toxic mutant of *Corynebacterium diphtheriae* toxin, in individuals 2 months-55 years, and a diphtheria toxoid-conjugate vaccine (Sanofi Pasteur Inc., Swiftwater, PA, USA), for use in individuals 9 months-55 years of age.

MenACWY-CRM has been shown to be immunogenic and well-tolerated in all ages where indicated \[[@B10]\]. Protective levels of antibodies against meningococcal serogroups were shown to persist to various degrees up to 5 years post-vaccination, in infants and toddlers \[[@B11][@B12]\], children 2--10 years of age \[[@B13][@B14]\], adolescents and adults \[[@B15][@B16][@B17]\]. However, their decline over time varies with the serogroup, age group, and the serum bactericidal activity assay (SBA) used to evaluate antibody response, either using human or rabbit (hSBA/rSBA) complement \[[@B18]\].

This study was conducted to generate evidence on 1-year antibody persistence and safety following MenACWY-CRM vaccination of infants from South Korea, after the vaccine\'s indication extended in the country to this age group in May 2014.

Materials and Methods
=====================

Study design and participants
-----------------------------

This phase IV, open-label study was conducted in six centers in South Korea, from July 2015 to December 2017. Healthy 2-month-old infants were eligible for enrollment if their parents/legally acceptable representatives provided written informed consent and were able and willing to comply with the study procedures, as assessed by the investigators. Infants who previously received any meningococcal vaccines, had a confirmed or suspected case of meningococcal disease, or had household contact/intimate exposure to a person with laboratory-confirmed *N. meningitidis* infection were not eligible for enrollment. A full list of inclusion and exclusion criteria is provided in [Supplementary Material](#S1){ref-type="supplementary-material"}.

Infants received a 4-dose vaccination series with MenACWY-CRM, administered at study months 0, 2, 4, and 10, corresponding to 2, 4, 6, and 12 months of age ([Fig. 1](#F1){ref-type="fig"}). Eligibility criteria were checked prior to each vaccine administration.

The vaccine\'s composition was previously described in detail \[[@B19]\]. Each dose (0.5 mL) was administered according to the prescribing information.

Study objectives
----------------

The primary objective was to evaluate the persistence of antibody responses against MenA, MenC, MenW, and MenY, measured by the percentages of participants with hSBA titers ≥8, as well as rSBA titers ≥8 and ≥128, at 1 year after the completion of the 4-dose vaccination series. Secondary objectives were to assess immune responses to MenACWY-CRM vaccination in terms of hSBA and rSBA geometric mean titers (GMTs) at 1-month and 1-year post-vaccination, as well as the percentages of participants with hSBA titers ≥8, rSBA titers ≥8 and ≥128 at 1 month after the completion of the 4-dose series.

The safety and tolerability of MenACWY-CRM were also assessed.

Immunogenicity assessment
-------------------------

For each participant, blood samples (approximately 5 mL per draw) were collected at 1 month and 1 year after the last vaccine dose ([Fig. 1)](#F1){ref-type="fig"} and tested using hSBA and rSBA, as previously described \[[@B20][@B21]\]. Testing was performed at the GSK Clinical Sciences Laboratory, Marburg, Germany (hSBA) and at Public Health England, UK (rSBA). The percentages of participants with hSBA titers ≥8 and rSBA ≥8 and ≥128, as well as hSBA and rSBA GMTs, were measured at both time points.

Safety and reactogenicity assessment
------------------------------------

Solicited local adverse events (AEs; injection site erythema, induration, and tenderness) and systemic AEs (change in eating habits, sleepiness, irritability, vomiting, diarrhea, fever \[body temperature ≥38.0℃\]) were recorded within 7 days (days 0--6) following each MenACWY-CRM dose. Use of analgesics/ antipyretics during the 7-day period post-vaccination was also recorded. Unsolicited AEs, medically-attended AEs, AEs leading to withdrawal from the study, and serious AEs (SAEs) were recorded throughout the study.

All AEs were graded by severity as mild (transient with no limitation in normal daily activity), moderate (some limitation in normal daily activity) or severe (diameter \>50 mm for injection site erythema and induration, temperature ≥40℃ for fever, and preventing normal daily activity for all other AEs). The relationship to study vaccination (not related, possibly related, or probably related) was assessed by the investigator for unsolicited AEs and SAEs.

Statistical analyses
--------------------

A sample size of 100 evaluable infants was requested by the South Korean health authority; assuming a 25% drop-out rate, a total of approximately 135 infants were to be enrolled in the study.

Immunogenicity analyses for primary and secondary objectives were conducted on the full analysis set (FAS), which included participants who received at least one vaccine dose and had available immunogenicity data at relevant time points. Immunogenicity analyses were also carried out in the per protocol set (PPS), which included FAS participants with no major protocol deviations. Safety analyses were performed on participants who received at least one vaccine dose and had relevant available safety data (solicited and unsolicited safety sets).

Persistence of the antibody response was summarized as the percentage of participants with hSBA/rSBA titers above the pre-specified thresholds, along with associated 2-sided 95% Clopper-Pearson confidence intervals (CIs) \[[@B22]\].

Titers below the assay\'s limit of detection were set at half the limit. Antibody GMTs with 2-sided 95% CIs were constructed by exponentiating (base 10) the means and CIs of the log~10-~transformed antibody titer. Geometric mean ratios (GMRs) between GMTs at 1 year and 1 month after completion of the vaccination schedule were calculated with 2-sided 95% CIs.

All statistical analyses were performed using SAS Institute Inc. (Cary, NC, USA).

Trademark statement
-------------------

*Menveo* is a trademark licensed to or owned by the GSK group of companies. *Menactra* is a trademark of Sanofi Pasteur.

Data sharing statement
----------------------

The results summary for this study (GSK study number 205336-NCT02446691) is available on the GSK Clinical Study Register and can be accessed at [www.gsk-clinicalstudyregister.com](http://www.gsk-clinicalstudyregister.com). For interventional studies that evaluate our medicines, anonymized patient-level data will be made available to independent researchers, subject to review by an independent panel, at [www.clinicalstudydatarequest.com](http://www.clinicalstudydatarequest.com) within 6 months of publication. To protect the privacy of patients and individuals involved in our studies, GSK does not publicly disclose patient-level data.

Ethics statement
----------------

The study protocol was approved by the institutional review boards (IRBs) of Seoul National University Hospital (IRB No. H-1503-079-656), Inha University Hospital (IRB No. 15-027), Ewha Womans University Mokdong Hospital (IRB No. EUMC 2015-03-006), Korea University Ansan Hospital (IRB No. AS15012), Chonbuk National University Hospital (IRB No. CUH 2015-03-037) and Seoul National University Bundang Hospital (IRB No. B-1504/293-006). Informed consent was confirmed by the IRBs. The study was conducted in compliance with the Declaration of Helsinki and followed International Committee on Harmonization Guidelines for Good Clinical Practice and is registered at [www.clinicaltrials.gov](http://www.ClinicalTrials.gov) ([NCT02446691](http://clinicaltrials.gov/ct2/show/NCT02446691)).

Results
=======

Demographics
------------

A total of 128 infants were enrolled in the study. All received at least one MenACWY-CRM dose, and 117 completed the study ([Fig. 1](#F1){ref-type="fig"}). Most infants who did not complete the study were lost to follow up. No premature withdrawals were caused by an AE.

The mean age of the infants at enrollment was 71.7 days. Overall, 54% of participants were male and 46% female. All infants but one (\>99%) were Asian ([Table 1](#T1){ref-type="table"}).

Human serum bactericidal activity results
-----------------------------------------

At 1 month after full vaccination with MenACWY-CRM, the percentage of participants with hSBA titers ≥8 ranged between 94% (MenA) and 100% (MenW and MenY). At 1-year post-vaccination (the timepoint of the primary immunogenicity objective), these percentages were 39% for MenA, 61% for MenC, 88% for MenW, and 89% for MenY ([Fig. 2A](#F2){ref-type="fig"}, [Supplementary Table 1](#S2){ref-type="supplementary-material"}).

At 1-month post-vaccination, hSBA GMTs varied from 107.9 (MenA) to 426.7 (MenW) and at 1-year post-vaccination, they ranged from 6.8 (MenA) to 53.6 (MenW) ([Fig. 2B](#F2){ref-type="fig"}, [Supplementary Table 1](#S2){ref-type="supplementary-material"}). The reverse cumulative distribution of hSBA titers is presented in [Supplementary Fig. 1](#S6){ref-type="supplementary-material"}. One-year versus 1-month post-vaccination GMRs ranged from 0.061 (MenA), and 0.14 (MenY) ([Supplementary Table 1](#S2){ref-type="supplementary-material"}).

Rabbit serum bactericidal activity results
------------------------------------------

At 1-month post-vaccination, ≥99% of children had rSBA titers ≥8 and ≥92% had titers ≥128 against each of the four meningococcal serogroups. At 1-year post-vaccination, the timepoint of the primary immunogenicity objective, the percentage of children with rSBA titers ≥8 was 54% for MenC, 69% for MenW, 90% for MenY and 99% for MenA; percentages of participants with rSBA titers ≥128 ranged between 30% (MenC) and 98% (MenA) ([Fig. 3A](#F3){ref-type="fig"}, [Supplementary Table 2](#S3){ref-type="supplementary-material"}).

rSBA GMTs ranged from 735.1 (MenC) to 7,394.2 (MenA) at 1-month post-vaccination, and from 17.2 (MenC) to 2,269.5 (MenA) at 1-year post-vaccination ([Fig. 3B](#F3){ref-type="fig"}, [Supplementary Table 2](#S3){ref-type="supplementary-material"}). The reverse cumulative distribution of rSBA titers is presented in [Supplementary Fig. 2](#S7){ref-type="supplementary-material"}. GMRs varied by serogroup, from 0.019 to 0.32 ([Supplementary Table 2](#S3){ref-type="supplementary-material"}).

Immunogenicity results for the PPS were similar to those obtained for the FAS ([Supplementary Table 3](#S4){ref-type="supplementary-material"}).

Safety and reactogenicity
-------------------------

Overall, at least one solicited AE was reported for 79% of children (38% for local AEs and 78% for systemic AEs), after any vaccine dose. The most frequently reported solicited local AE after each vaccination was injection-site tenderness, for 11%--16% of participants. The most frequently solicited systemic AEs were irritability, reported for 36%--45% of children, and sleepiness, reported for 16%--41% of children, across all vaccinations. Most solicited AEs were mild or moderate in nature, with severe solicited AEs being reported for ≤4% of children ([Table 2](#T2){ref-type="table"}).

At least one unsolicited AE was reported for 85 children (66%); all were medically-attended and one AE (diarrhea) was considered as possibly related to vaccination ([Table 3](#T3){ref-type="table"}). The most frequent unsolicited AEs were upper respiratory tract infection, reported in 34 children (27%), bronchiolitis in 15 children (12%), and nasopharyngitis in 15 children (12%). Most unsolicited AEs were mild to moderate in intensity and resolved before study termination.

Throughout the study, a total of 36 SAEs (detailed in [Supplementary Table 4](#S5){ref-type="supplementary-material"}) were reported in 26 children (20%). All were recovered/resolved by the end of study and none was assessed as related to vaccination ([Table 3](#T3){ref-type="table"}). There were no deaths reported during the study.

Discussion
==========

In the absence of circulating bactericidal antibodies, meningococcal disease can progress so rapidly that otherwise healthy individuals can become severely ill or can die within a few hours. This study is the first to assess, using both hSBA and rSBA, the antibody persistence at 1 year following a 4-dose infant priming series of MenACWY-CRM. Infant priming with the quadrivalent meningococcal CRM-conjugate vaccine elicited levels of bactericidal antibodies assumed to be protective against three epidemiologically relevant serogroups (MenC, MenW, and MenY) that were maintained for at least 1 year in ≥54% of children. When persistence of immune responses was assessed against MenA, the percentage of participants with SBA titers ≥8 was lower when tested by hSBA than by rSBA (39% vs. 99%) 1-year post-vaccination.

The antibody persistence observed in this South Korean study is similar to that reported from a previous study conducted in the United States, which showed a wane in seroprotection rates, at 60 months following a 4-dose MenACWY-CRM infant schedule \[[@B18]\]. Across MenCWY serogroups, the percentages of participants with SBA titers ≥8 ranged between 26% (MenC) and 68% (MenW) with hSBA, and between 27% (MenC) and 71% (MenY) with rSBA. However, as in the current study, the decline was more pronounced for MenA when the hSBA was used (6% of participants with titers ≥8, compared to 96% of participants with rSBA titers ≥8) \[[@B18]\].

A similar observation showing no correlation between hSBA and rSBA for MenA was reported in a study evaluating the antibody persistence at 3 years after MenACWY-CRM vaccine administration in adolescents \[[@B15]\]. The percentages of participants with hSBA titers ≥8 against MenA were lower when assessed by hSBA (28%) compared with rSBA (96%). Similar results were observed in the same study when the antibody persistence to the comparator vaccine MenACWY-D was tested using the two assays \[[@B15]\]. The wane in hSBA titers and the relative lower percentages of participants with protective antibody levels (≥8) especially against MenA seem to constitute an assay-specific phenomenon which is not also observed when using rSBA.

While hSBA has been widely used to assess immune responses, there is mounting evidence that use of human complement in the SBA may not be optimal for assessing long-term antibody persistence, especially against MenA. Use of the baby rabbit complement SBA may be more appropriate \[[@B23]\], and the rSBA assay is also included in the World Health Organization-recommended procedure for evaluation of meningococcal vaccines \[[@B20]\]. The differences between rSBA and hSBA titers are thought to be due, at least partially, to meningococcal factor H binding protein, which binds specifically to human factor H to ultimately enable evasion of complement-mediated killing. Relatedly, it has been shown that human antibody subclasses may differentially interact with human and rabbit complement \[[@B23]\].

The immunogenicity results obtained in the current trial at 1-month post-MenACWY-CRM vaccination are also consistent with previous studies in infants. In a pivotal study in the United States where infants received the same vaccination schedule, 94%--100% of children had hSBA titers ≥8 against each of the meningococcal serogroups 1 month after schedule completion \[[@B24]\]. In another clinical trial, 96%--99% of infants had hSBA titers ≥8 against all four serogroups at 1 month following vaccination with four MenACWY-CRM doses, administered at 2, 4, 6, and 12 months of age \[[@B25]\]. Similar results were also observed following a 3-dose series of MenACWY-CRM, with 89%--98% of infants achieving hSBA titers ≥8 at 1-month post-vaccination \[[@B26]\]. All these trials also demonstrated that co-administration of MenACWY-CRM with routine pediatric vaccines did not impact the immune responses against meningococcal serogroups.

Safety data collected in the current study were similar with those from previous reports in infants after a vaccination with MenACWY-CRM in infants \[[@B24][@B26][@B27]\]. These consistent results further confirm the acceptable clinical safety profile observed in all studied age groups, including in Asian populations \[[@B28][@B29][@B30]\].

Potential limitations of the study included the fact that baseline antibody levels were not evaluated; however, the magnitude of immune responses against all serogroups at 1-month post-vaccination with MenACWY-CRM were consistent with the evidence generated from previous studies in infants \[[@B10]\].

In view of the dynamic epidemiology of IMD and its potential severe, long-term sequalae, vaccination against all meningococcal serogroups, including MenA, MenC, MenW, and MenY remains important for public health, even considering the relatively low disease incidence in South Korea.

In conclusion, a 4-dose infant priming vaccination series with MenACWY-CRM was able to induce robust immune responses in infants from South Korea, and hSBA/rSBA titers ≥8 for all four meningococcal serogroups were sustained in 39%--99% of children up to 1 year after schedule completion. No new concerns were raised with respect to the safety and tolerability of MenACWY-CRM.
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###### Supplemental Material

###### Supplementary Table 1

Summary of hSBA immunogenicity results (hSBA full analysis set)

###### Supplementary Table 2

Summary of rSBA immunogenicity results (rSBA full analysis set)

###### Supplementary Table 3

Summary of immunogenicity results for the per-protocol set

###### Supplementary Table 4

Listing of serious adverse events from day 0 to study end, by system organ class and preferred term (overall safety set)

###### Supplementary Fig. 1

Reverse cumulative distributions of hSBA titers (full analysis set). (A) MenA. (B) MenC. (C) MenW. (D) MenY. hSBA, serum bactericidal assay using human complement; M, month; post-vac, post-vaccination with four MenACWY-CRM doses; Y, year.

###### Supplementary Fig. 2

Reverse cumulative distributions of rSBA titers (full analysis set). (A) MenA. (B) MenC. (C) MenW. (D) MenY. rSBA, serum bactericidal assay using rabbit complement; M, month; post-vac, post-vaccination with four MenACWY-CRM doses; Y, year.

![Participant flow chart. M, study month; FAS, full analysis set; hSBA, serum bactericidal assay using human complement; rSBA, serum bactericidal assay using rabbit complement.](cevr-8-94-g001){#F1}

![(A, B) Immune responses evaluated using hSBA (full analysis set). hSBA, serum bactericidal assay using human complement; GMT, geometric mean titer; A, MenA; C, MenC; W, MenW; Y, MenY. Error bars represent 95% confidence intervals.](cevr-8-94-g002){#F2}

![(A, B) Immune responses evaluated using rSBA (full analysis set). rSBA, serum bactericidal assay using rabbit complement; GMT, geometric mean titer; A, MenA; C, MenC; W, MenW; Y, MenY. Error bars represent 95% confidence intervals.](cevr-8-94-g003){#F3}

###### Participants\' characteristics at enrolment

![](cevr-8-94-i001)

                Enrolled set (n=128)
  ------------- ----------------------
  Age (day)     71.7±8.1
  Female sex    59 (46)
  Race          
   Asian        127 (99)
   Other        1 (1)
  Weight (kg)   6.1±0.7
  Height (cm)   59.5±2.7

Values are presented as mean±SD or number (%).

###### Number and percentage of participants with reported solicited adverse events within the 7-days period after each vaccine dose (solicited safety set)

![](cevr-8-94-i002)

                             1st dose (n=128)   2nd dose (n=128)   3rd dose (n=127)   4th dose (n=124)
  -------------------------- ------------------ ------------------ ------------------ ------------------
  Local adverse event                                                                 
   Erythema                  4 (3)              6 (5)              1 (1)              6 (5)
    Severe                   0                  0                  1 (1)              2 (2)
   Induration                4 (3)              9 (7)              3 (2)              6 (5)
    Severe                   0                  0                  0                  2 (2)
   Tenderness                17 (13)            21 (16)            14 (11)            20 (16)
    Severe                   0                  0                  3 (2)              2 (2)
  Systemic adverse event                                                              
   Change in eating habits   29 (23)            21 (16)            21 (17)            24 (19)
    Severe                   2 (2)              0                  0                  3 (2)
   Sleepiness                52 (41)            31 (24)            28 (22)            20 (16)
    Severe                   2 (2)              0                  0                  4 (3)
   Irritability              58 (45)            49 (38)            47 (37)            45 (36)
    Severe                   2 (2)              3 (2)              4 (3)              5 (4)
   Vomiting                  26 (20)            20 (16)            15 (12)            5 (4)
    Severe                   0                  1 (1)              0                  1 (1)
   Diarrhea                  15 (12)            13 (10)            15 (12)            17 (14)
    Severe                   0                  1 (1)              0                  0
   Fever (≥38℃)              4 (3)              10 (8)             6 (5)              15 (12)

Values are presented as number (%).

###### Number and percentage of participants with reported unsolicited adverse events after any vaccination, up to study end (unsolicited safety set, n=128)

![](cevr-8-94-i003)

                               No. (%)
  ---------------------------- ---------
  Any unsolicited AEs          85 (66)
   At least possibly related   1 (1)
  SAEs                         26 (20)
   At least possibly related   0
  Medically attended AEs       85 (66)
   At least possibly related   1 (1)
  AEs leading to withdrawal    0
  AEs leading to death         0

AE, adverse event; SAE, serious AE.
